The FDA began establishing Standards of Identity (SOI) in 1939 and has since put into place more than 250 of the consumer protections.

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency's drug program.

FDA Commissioner Marty Makary, M.D., has made his pick for the next director of the FDA’s Center for Drug Evaluation and Research (CDER) in veteran biotech executive George Tidmarsh, M.D., Ph.D.

The FDA in 2022 announced a ban on the sale of Juul e-cigarettes nationwide, saying the company did not prove that keeping its products on the market “would be appropriate for the protection of ...

The FDA has approved another natural dye for use in foods, continuing its war on artificial, petroleum-based food colorings. The new color is gardinea ...

NBC News medical contributor Dr. Natalie Azar reports on the FDA panel discussion of the use of antidepressants during pregnancy. The panel shared misinformation and facts taken out of context ...

Stanford's George Tidmarsh has authored 143 scientific papers and patents, as well as played a central role in developing seven FDA-approved drugs.

FDA Commissioner Dr. Marty Makary joins Morning Joe to address the agency’s controversial decision to keep Juul e-cigarettes on the market, ongoing reviews of mifepristone, and the latest ...

The FDA cracked down on two plants in India and one in Korea in separate recently released reports, citing issues ranging from mold to skirted testing procedures. | The FDA listed observations at ...

Tidmarsh, from the FDA, assured the pro-fluoride contingent that if supplements are banned, there is still one way to get them back on the market: as a drug.

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to receive complete response letters from the new-look agency.

Find specific lot numbers on the FDA's website. A press release has not been issued for the recall as of yet. The status of the recall is ongoing.